Synonyms: C188-9 [2] | TTI 101 | TTI101
Compound class:
Synthetic organic
Comment: TTI-101(formerly C188-9) is an orally bioavailable STAT3 transcription factor inhibitor. It blocks the tyrosine residue phosphorylation by Janus kinase (JAK) that mediates STAT3 activation, leading to downregulation of STAT3-mediated gene expression. This mechanism of action is considered as a valid approach for the treatment of inflammation, fibrosis, and a range of cancers [1,3].
|
|
References |
1. Bharadwaj U, Kasembeli MM, Robinson P, Tweardy DJ. (2020)
Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 to Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution. Pharmacol Rev, 72 (2): 486-526. [PMID:32198236] |
2. Brotherton-Pleiss C, Yue P, Zhu Y, Nakamura K, Chen W, Fu W, Kubota C, Chen J, Alonso-Valenteen F, Mikhael S et al.. (2021)
Discovery of Novel Azetidine Amides as Potent Small-Molecule STAT3 Inhibitors. J Med Chem, 64 (1): 695-710. [PMID:33352047] |
3. Jung KH, Yoo W, Stevenson HL, Deshpande D, Shen H, Gagea M, Yoo SY, Wang J, Eckols TK, Bharadwaj U et al.. (2017)
Multifunctional Effects of a Small-Molecule STAT3 Inhibitor on NASH and Hepatocellular Carcinoma in Mice. Clin Cancer Res, 23 (18): 5537-5546. [PMID:28533225] |
4. Xu X, Kasembeli MM, Jiang X, Tweardy BJ, Tweardy DJ. (2009)
Chemical probes that competitively and selectively inhibit Stat3 activation. PLoS One, 4 (3): e4783. [PMID:19274102] |